BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28

• 

  Drug Development

  Rivus’ Drug Shows Unique Reduction of Fat without Muscle Loss

  Statistically significant weight loss and liver fat reduction were seen across all dosage groups—with no changes to diet or exercise.

  February 9, 2022

   · 

  3 min read

   · 

  Hannah Chudleigh
• 

  BioCapital

  Novavax Under Fire for COVID-19 Vaccine Delays

  A week after Novavax submitted its Emergency Use Authorization materials to the FDA for its COVID-19 vaccine candidate. reports are coming out about the company’s problems with the production and delivery.

  February 9, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Pharm Country

  J&J Pauses COVID-19 Vaccine Production at Netherlands Facility

  Johnson & Johnson has temporarily paused production of its COVID-19 vaccine at its manufacturing site in The Netherlands.

  February 9, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  FDA

  Lilly, Innovent Cancer Drug Not Likely to Enjoy Regulatory Flexibility

  It’s not likely that the FDA will give the cancer drug sintilimab immediate attention, since the research was conducted exclusively in China.

  February 9, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Pharm Country

  COVID-19 Update: Therapeutic Hits and Misses and an Effective Nasal Spray

  The COVID-19 pandemic has seen a full-blown effort from biopharma and researchers to develop new drugs and test old ones against the disease, with highly mixed results.

  February 9, 2022

   · 

  4 min read

   · 

  Mark Terry
• 

  FDA

  China-Developed Drugs for U.S. Market Could Face Steep Hill

  The FDA is slowing down the process of potentially approving dozens of new medications initially developed for the Chinese market.

  February 9, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Business

  Ventus will Aim $140 Million at Previously Undruggable Targets

  Ventus Therapeutics has raised $140 million in a Series C financing round less than two years after launching to develop therapies aimed at diseases of the innate immune system.

  February 9, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  BioSpace Investigates Challenges with Compensation Disparity in the Life Sciences

  72% of employers are currently experiencing a decrease in the volume of candidates applying to their jobs.

  February 9, 2022

   · 

  6 min read

   · 

  Heather McKenzie
• 

  Business

  GSK Posts Strong 2021 as Demerger Countdown Begins

  As GSK moves into the new year, Chief Executive Officer Emma Walmsley predicted 2022 will be a “landmark year” for the company.

  February 9, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Business

  Global Roundup: Celltrion Prepares to Trap COVID-19 in Phase III

  Biopharma and life sciences organizations from across the globe provide updates on their businesses and pipelines.

  February 9, 2022

   · 

  6 min read

   · 

  Alex Keown